In rheumatoid arthritis (RA), the presence of variable domain glycans (VDGs) has been described in B cell-producing anti-citrullinated protein antibodies (ACPAs) due to SHM events, which results in the selective introduction of N-linked glycosylation sites in the BCR; this is presumed to act as an important driver of RA development [84,85]. This evidence concerns the gene BCR and rheumatoid arthritis.